ANZCTR search results

The purpose of this research is to investigate the effects of a rice bran arabinoxylan compound (RBAC) as a nutritional supplement on the health-related quality of life (QoL) of cancer patients. Who is it for? You may be eligible for this study if you are between 18 and 70 years old, diagnosed with any solid organ cancer, and currently undergoing active treatment. Study details Participants in this study will be randomised by chance into two groups. One group will consume 3g per day of the study compound (RBAC) packed in sachets for 24 weeks. The other group will take an inactive placebo treatment for the same period. The assigned intervention will be in addition to your usual cancer care. As part of the study, all participants will complete questionnaires, be weighed and provide blood and stool samples. Results from this research can improve the understanding of the effect of RBAC during cancer treatment, inform the planning of a larger trial, and supply data to validate the immuno-therapeutic benefits of RBAC.

This study aims to determine whether dietary supplementation with L-serine improves clinical effects of hereditary sensory neuropathy type 1 (HSN1). The most prevalent form of HSN1 is caused by variations (mutations) in the serine palmitoyltransferase (SPT) gene. Deoxysphingolipid bases are toxic by-products produced by mutations in the SPT gene. In a rat model of HSN1, dietary supplementation with the amino acid, L-serine, reduced levels of deoxysphingolipid bases (Garofalo K, Penno A, Schmidt BP, et al. Oral L-serine supplementation reduces production of neurotoxic deoxysphingolipids in mice and humans with hereditary sensory autonomic neuropathy type 1. J Clin Invest 2011;121:4735-4745). Serine treatment may prevent the clinical accompaniments of this disease which include sensory loss, insensitivity to pain and varying degrees of muscle weakness and wasting. Frequent complications in HSN1 are foot ulceration's, infections and limb amputations. We wish to determine the power of various modalities of testing (skin sensitivity testing, skin biopsy and standard clinical and neurophysiology measures) for a larger trial.

Periodontitis, especially stage III and IV, grade C periodontitis carries significant chances of tooth loss. Adjunctive systemic antimicrobials may provide additional benefits in these patients, however, the evidence is unclear. If the adjunctive antimicrobial has additional anti-inflammatory properties it may help in the modulation of the host response. Azithromycin is one such antimicrobial with additional host-modulating properties. Although the anti-microbial properties of azithromycin have been studied extensively, there are few studies on its host-modulating properties in periodontitis. It is hypothesized that adjunctive administration of azithromycin will result in decreased periodontal inflamed surface area scores, gain in clinical attachment level, reduced pocket depth, decreased levels of pro-inflammatory cytokines in the gingival crevicular fluid & saliva and decrease in the number of pathogenic bacteria in the periodontal pockets.

The proposed project will evaluate the feasibility, acceptability and preliminary effectiveness of a telephone delivered intervention that targets problematic alcohol consumption in young people living with severe mental ill-health (SMI). Analysis will focus on issues associated with recruitment, ongoing engagement of participants, and satisfaction with the intervention. We will also examine changes in alcohol consumption and mental health symptomatology at follow-up. The randomised pilot trial compares the effects of two interventions: Quik Fix (2 session brief intervention) vs a 10 session Transdiagnostic CBT (TrCBT) intervention. Additional goals include • increasing the identification of young Australians experiencing comorbid SMI and hazardous alcohol use; • providing greater access to evidence-based treatments;

Right hepatectomy involves removal of a significant amount of liver parenchymal tissue and a lot of planning is required to ensure avoiding the inherent risks of major haemorrhage and severe hypotension. Over the last two decades, there have been the development of Enhanced Recovery After Surgery (ERAS) programmes particular for liver resections, aimed at reducing overall morbidity and length of hospital stay. . The traditional approach at Austin health focuses on “restrictive” fluid therapy, guided by “low central venous pressure anaesthesia” during liver resections. A second approach has been developed, which uses a surgery-specific cardiac output-guided algorithm for patients undergoing complex liver resection. This algorithm has been modified from another algorithm that has been used for pancreatic surgery. The aim of the study is to evaluate the two fluid intervention strategies and their differences in the use of intraoperative fluid, vasoactive medications, post-operative complications and hospital length of stay. This is a retrospective observational study that looked at patients undergoing major right hepatectomy with usual care or “traditional” restrictive fluid therapy & low CVP anaesthesia, compared to those who were managed with the surgery-specific cardiac output algorithm. It is hypothesised that the surgery-specific cardiac output-guided algorithm improves length of hospital stay and reduces morbidity and post-operative complications in major right hepatectomy.

The aim of this study is to define the dose of early rehabilitation intervention that provides the most benefit for people with ischaemic stroke of mild and moderate severity. 4 separate rehabilitation intervention regimens (different number, length and intensity of training sessions) will be implemented by physiotherapists and nurses in stroke units immediately post stroke. Participants will be followed up at 3 and 6 months post stroke. 2,700 patients with mild to moderate stroke will be recruited in Australia, New Zealand, Singapore, Malaysia, India and the UK. We hypothesise that the optimal dose intervention regimen will result in an improved outcome at 3 months post stroke, with less complications at 14 days and better quality of life at 6 months post stroke.

The purpose of this study is to investigate the safety of low-dose lenalidomide treatment after allogeneic stem cell transplantation for patients with acute myeloid leukaemia or myelodysplastic syndromes at high risk of relapse. Who is it for? You may be eligible to join this study if you are aged 18 years or above, and have been diagnosed with either high risk acute myeloid leukaemia (AML), OR high risk myelodysplastic syndrome (MDS). Study details All participants in this study will undergo treatment with the drug, lenalidomide, which will commence between day 40-45 after allogeneic stem cell transplant. Lenalidomide is an oral tablet, which will be taken for up to 48 weeks. The dose of lenalidomide in the study will commence at 2.5mg once per week, with subsequent groups increasing to 2.5mg twice per week, 5mg twice per week, 5mg every second day, 10mg every second day. Each participant will be assigned to receive one dose level for the entire study. The safety of lenalidomide treatment will be assessed by the incidence of side effects 120 days after starting the first dose of lenalidomide. This study will determine the safest dose of lenalidomide after allogeneic transplantation for patients at high risk of relapse.

The most commonly employed paeidtric procedural analgosedatives (PAS) over the past few decades have been both nitrous oxide (N2O) and ketamine. This is a prospective randomised comparison trial comparing inhaled N2O plus INF to IV ketamine for paediatric patients requiring PAS for fracture reduction. We hypothesis that N2O plus INF is equivalent to ketamine regarding overall procedural analgosedative efficacy for the patient in addition to being more cost-effective given the quicker offset of action and consequent shorter length of stay plus the requirement for fewer and less specialised medical personnel.

The purpose of this study is to help us to learn know more about Flinders University students food and eating habits, access to food, and nutrition knowledge and literacy. These findings will help to inform, tailor and target activities of the Nutrition Promotion for Flinders Student Health and Wellbeing Project to the nutrition needs of students studying at Flinders University.

The purpose of the study is to investigate whether a virtual reality exposure therapy program, delivered using 360 degree videos, can reduce public speaking anxiety compared to a neutral 360 video control. We expect that the 360 video program will lead to decreased public speaking anxiety at 2 weeks post-intervention compared to the control.